Scheie Syndrome
6 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I (NCT00852358) | Patricia I. Dickson, M.D. | 2009-06-01 |
| Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I (NCT00786968) | Patricia I. Dickson, M.D. | 2008-01-01 |
| Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease (NCT00258011) | Genzyme, a Sanofi Company | 2005-12-01 |
| A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease (NCT00144781) | Genzyme, a Sanofi Company | 2004-12-01 |
| A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old (NCT00146757) | Genzyme, a Sanofi Company | 2002-10-01 |
| Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients (NCT00146770) | Genzyme, a Sanofi Company | 2001-05-01 |
Track Scheie Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.